In the IMpower 150 study, a combination of atezolizumab and bevacizumab plus chemotherapy significantly improved PFS and OS in patients with EGFR mutations and advanced NSCLC, including those with prior TKI failure or with liver metastasis [27]. Here, EGFR is linked to non-small cell lung carcinoma.